Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
8/31/2010 10:07:02 AM
STOCKHOLM--(BUSINESS WIRE)--Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care1 for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile. Data from the pivotal Phase 3 EINSTEIN-DVT clinical trial were presented today during a Hot Line session at the European Society of Cardiology (ESC) Congress in Stockholm, Sweden.
comments powered by